Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Mar:41:110-7.
doi: 10.1016/j.cct.2015.01.005. Epub 2015 Jan 17.

Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial

Joshua D Lee  1 , Peter D Friedmann  2 , Tamara Y Boney  3 , Randall A Hoskinson Jr  2 , Ryan McDonald  4 , Michael Gordon  5 , Marc Fishman  6 , Donna T Chen  7 , Richard J Bonnie  8 , Timothy W Kinlock  9 , Edward V Nunes  10 , James W Cornish  3 , Charles P O'Brien  3
Affiliations
Randomized Controlled Trial

Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial

Joshua D Lee et al. Contemp Clin Trials. 2015 Mar.

Abstract

Background: Extended-release naltrexone (XR-NTX, Vivitrol; Alkermes Inc.) is an injectable monthly sustained-release mu opioid receptor antagonist. XR-NTX is a potentially effective intervention for opioid use disorders and as relapse prevention among criminal justice system (CJS) populations.

Methods: This 5-site open-label randomized controlled effectiveness trial examines whether XR-NTX reduces opioid relapse compared with treatment as usual (TAU) among community dwelling, non-incarcerated volunteers with current or recent CJS involvement. The XR-NTX arm receives 6 monthly XR-NTX injections at Medical Management visits; the TAU group receives referrals to available community treatment options. Assessments occur every 2 weeks during a 24-week treatment phase and at 12- and 18-month follow-ups. The primary outcome is a relapse event, defined as either self-report or urine toxicology evidence of ≥10 days of opioid use in a 28-day (4 week) period, with a positive or missing urine test counted as 5 days of opioid use.

Results: We describe the rationale, specific aims, and design of the study. Alternative design considerations and extensive secondary aims and outcomes are discussed.

Conclusions: XR-NTX is a potentially important treatment and relapse prevention option among persons with opioid dependence and CJS involvement. ClinicalTrials.gov: NCT00781898.

Keywords: Criminal justice; Extended-release naltrexone; Naltrexone; Opioid relapse prevention.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Lee has received investigator initiated study funding and study drug in-kind from Alkermes and Reckitt Benckiser for additional studies. Drs. Gordon and Kinlock received investigator initiated study funding and study drug in-kind from Alkermes for an additional study. Dr. Nunes has received: medication in-kind for research studies from Alkermes/Cephalon, Inc., Reckitt-Benckiser, and Duramed Pharmaceuticals; web-based behavioral intervention for research study from HealthSim, LLC; devices under investigation and reimbursement for travel for investigators’ meeting from Brainsway. He was paid an honorarium and received reimbursement for travel for attendance at a Lilly Advisory Board Meeting in January 2012 and received educational materials from Otsuka America Pharmaceutical, Inc. in 2013. He plans to serve on Advisory Board for Alkermes in October 2014. Dr. O’Brien has served as a consultant to Alkermes.

Figures

Figure 1
Figure 1
Study Flow, Inclusion/Exclusion Criteria, and Outcomes
See this image and copyright information in PMC

References

    1. Office of National Drug Control Policy. 2013 Annual Report, Arrestee Drug Abuse Monitoring Program II. Washington, DC: Executive Office of the President; 2014.
    1. Lee JD, Rich JD. Opioid pharmacotherapy in criminal justice settings: now is the time. Subst Abus. 2012;33(1):1–4. - PubMed
    1. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8. - PMC - PubMed
    1. Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600. - PMC - PubMed
    1. Degenhardt L, Larney S, Kimber J, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014 Aug;109(8):1306–17. - PubMed

Publication types

Associated data